Global Clinical Trials 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR062414710

Publication Date:

June 26, 2024

Pages:

103

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Clinical Trials market size was valued at USD 48020 million in 2023 and is forecast to a readjusted size of USD 63030 million by 2030 with a CAGR of 4.0% during review period.
Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison. Clinical trials generate data on safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial 鈥� their approval does not mean that the therapy is 'safe' or effective, only that the trial may be conducted.
The industry's leading producers are Parexel, PRA Health and LabCorp (Covance), which accounted for 4.94%, 7.25% and 11.81% of revenue in 2019, respectively. By region, North America has the highest share of income, at more than 39 percent.
This report includes an overview of the development of the Clinical Trials industry chain, the market status of Small Molecules (Phase I, Phase II), Biologics (Phase I, Phase II), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Clinical Trials.
Regionally, the report analyzes the Clinical Trials markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Clinical Trials market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Clinical Trials market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Clinical Trials industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Phase I, Phase II).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Clinical Trials market.
Regional Analysis: The report involves examining the Clinical Trials market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Clinical Trials market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Clinical Trials:
Company Analysis: Report covers individual Clinical Trials players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Clinical Trials This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Small Molecules, Biologics).
Technology Analysis: Report covers specific technologies relevant to Clinical Trials. It assesses the current state, advancements, and potential future developments in Clinical Trials areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Clinical Trials market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Clinical Trials market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Phase I
Phase II
Phase III
Phase IV
麻豆原创 segment by Application
Small Molecules
Biologics
麻豆原创 segment by players, this report covers
IQVIA
Charles River Laboratory
ICON Plc
Labcorp Drug Development
Parexel
PPD, Inc. (Thermo Fisher)
Syneos Health
Wuxi AppTec Inc.
Tigermed Consulting
Boji Medical
Medpace Holdings, Inc.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Clinical Trials product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Clinical Trials, with revenue, gross margin and global market share of Clinical Trials from 2019 to 2024.
Chapter 3, the Clinical Trials competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Clinical Trials market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Clinical Trials.
Chapter 13, to describe Clinical Trials research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope of Clinical Trials
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Clinical Trials by Type
1.3.1 Overview: Global Clinical Trials 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Clinical Trials Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Phase I
1.3.4 Phase II
1.3.5 Phase III
1.3.6 Phase IV
1.4 Global Clinical Trials 麻豆原创 by Application
1.4.1 Overview: Global Clinical Trials 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Small Molecules
1.4.3 Biologics
1.5 Global Clinical Trials 麻豆原创 Size & Forecast
1.6 Global Clinical Trials 麻豆原创 Size and Forecast by Region
1.6.1 Global Clinical Trials 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Clinical Trials 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Clinical Trials 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Clinical Trials 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Clinical Trials 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Clinical Trials 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Clinical Trials 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 IQVIA
2.1.1 IQVIA Details
2.1.2 IQVIA Major Business
2.1.3 IQVIA Clinical Trials Product and Solutions
2.1.4 IQVIA Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 IQVIA Recent Developments and Future Plans
2.2 Charles River Laboratory
2.2.1 Charles River Laboratory Details
2.2.2 Charles River Laboratory Major Business
2.2.3 Charles River Laboratory Clinical Trials Product and Solutions
2.2.4 Charles River Laboratory Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Charles River Laboratory Recent Developments and Future Plans
2.3 ICON Plc
2.3.1 ICON Plc Details
2.3.2 ICON Plc Major Business
2.3.3 ICON Plc Clinical Trials Product and Solutions
2.3.4 ICON Plc Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 ICON Plc Recent Developments and Future Plans
2.4 Labcorp Drug Development
2.4.1 Labcorp Drug Development Details
2.4.2 Labcorp Drug Development Major Business
2.4.3 Labcorp Drug Development Clinical Trials Product and Solutions
2.4.4 Labcorp Drug Development Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Labcorp Drug Development Recent Developments and Future Plans
2.5 Parexel
2.5.1 Parexel Details
2.5.2 Parexel Major Business
2.5.3 Parexel Clinical Trials Product and Solutions
2.5.4 Parexel Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Parexel Recent Developments and Future Plans
2.6 PPD, Inc. (Thermo Fisher)
2.6.1 PPD, Inc. (Thermo Fisher) Details
2.6.2 PPD, Inc. (Thermo Fisher) Major Business
2.6.3 PPD, Inc. (Thermo Fisher) Clinical Trials Product and Solutions
2.6.4 PPD, Inc. (Thermo Fisher) Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 PPD, Inc. (Thermo Fisher) Recent Developments and Future Plans
2.7 Syneos Health
2.7.1 Syneos Health Details
2.7.2 Syneos Health Major Business
2.7.3 Syneos Health Clinical Trials Product and Solutions
2.7.4 Syneos Health Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Syneos Health Recent Developments and Future Plans
2.8 Wuxi AppTec Inc.
2.8.1 Wuxi AppTec Inc. Details
2.8.2 Wuxi AppTec Inc. Major Business
2.8.3 Wuxi AppTec Inc. Clinical Trials Product and Solutions
2.8.4 Wuxi AppTec Inc. Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Wuxi AppTec Inc. Recent Developments and Future Plans
2.9 Tigermed Consulting
2.9.1 Tigermed Consulting Details
2.9.2 Tigermed Consulting Major Business
2.9.3 Tigermed Consulting Clinical Trials Product and Solutions
2.9.4 Tigermed Consulting Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Tigermed Consulting Recent Developments and Future Plans
2.10 Boji Medical
2.10.1 Boji Medical Details
2.10.2 Boji Medical Major Business
2.10.3 Boji Medical Clinical Trials Product and Solutions
2.10.4 Boji Medical Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Boji Medical Recent Developments and Future Plans
2.11 Medpace Holdings, Inc.
2.11.1 Medpace Holdings, Inc. Details
2.11.2 Medpace Holdings, Inc. Major Business
2.11.3 Medpace Holdings, Inc. Clinical Trials Product and Solutions
2.11.4 Medpace Holdings, Inc. Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Medpace Holdings, Inc. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Clinical Trials Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Clinical Trials by Company Revenue
3.2.2 Top 3 Clinical Trials Players 麻豆原创 Share in 2023
3.2.3 Top 6 Clinical Trials Players 麻豆原创 Share in 2023
3.3 Clinical Trials 麻豆原创: Overall Company Footprint Analysis
3.3.1 Clinical Trials 麻豆原创: Region Footprint
3.3.2 Clinical Trials 麻豆原创: Company Product Type Footprint
3.3.3 Clinical Trials 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Clinical Trials Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Clinical Trials 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Clinical Trials Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Clinical Trials 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Clinical Trials Consumption Value by Type (2019-2030)
6.2 North America Clinical Trials Consumption Value by Application (2019-2030)
6.3 North America Clinical Trials 麻豆原创 Size by Country
6.3.1 North America Clinical Trials Consumption Value by Country (2019-2030)
6.3.2 United States Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Clinical Trials Consumption Value by Type (2019-2030)
7.2 Europe Clinical Trials Consumption Value by Application (2019-2030)
7.3 Europe Clinical Trials 麻豆原创 Size by Country
7.3.1 Europe Clinical Trials Consumption Value by Country (2019-2030)
7.3.2 Germany Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Clinical Trials Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Clinical Trials Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Clinical Trials 麻豆原创 Size by Region
8.3.1 Asia-Pacific Clinical Trials Consumption Value by Region (2019-2030)
8.3.2 China Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Clinical Trials Consumption Value by Type (2019-2030)
9.2 South America Clinical Trials Consumption Value by Application (2019-2030)
9.3 South America Clinical Trials 麻豆原创 Size by Country
9.3.1 South America Clinical Trials Consumption Value by Country (2019-2030)
9.3.2 Brazil Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Clinical Trials Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Clinical Trials Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Clinical Trials 麻豆原创 Size by Country
10.3.1 Middle East & Africa Clinical Trials Consumption Value by Country (2019-2030)
10.3.2 Turkey Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Clinical Trials 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Clinical Trials 麻豆原创 Drivers
11.2 Clinical Trials 麻豆原创 Restraints
11.3 Clinical Trials Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Clinical Trials Industry Chain
12.2 Clinical Trials Upstream Analysis
12.3 Clinical Trials Midstream Analysis
12.4 Clinical Trials Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

IQVIA
Charles River Laboratory
ICON Plc
Labcorp Drug Development
Parexel
PPD, Inc. (Thermo Fisher)
Syneos Health
Wuxi AppTec Inc.
Tigermed Consulting
Boji Medical
Medpace Holdings, Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.